- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05013281
Suprachoroidal Hemorrhage Associated With Pars Plana Vitrectomy
August 17, 2021 updated by: Beijing Tongren Hospital
To analyze the characteristics, related risk factors, and prognosis of suprachoroidal hemorrhage (SCH) associated with pars plana vitrectomy (PPV).
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
28
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100730
- Beijing Tongren Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
any participants who treated with PPV and occured Suprachoroidal hemorrhage with PPV
Description
Inclusion Criteria:
- Suprachoroidal hemorrhage associated with pars plana vitrectomy
Exclusion Criteria:
- Patients with eye trauma-related Suprachoroidal hemorrhage were excluded.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
pathogenesis
Time Frame: baseline
|
pathogenesis of PPV-related SCH and incidence of PPV-related SCH
|
baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
vision acuity
Time Frame: up to 7 weeks
|
the final vision acuity
|
up to 7 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2010
Primary Completion (Actual)
June 30, 2020
Study Completion (Actual)
January 28, 2021
Study Registration Dates
First Submitted
August 11, 2021
First Submitted That Met QC Criteria
August 17, 2021
First Posted (Actual)
August 19, 2021
Study Record Updates
Last Update Posted (Actual)
August 19, 2021
Last Update Submitted That Met QC Criteria
August 17, 2021
Last Verified
July 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TR2021SCH
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pars Plana Vitrectomy
-
Yonsei UniversityCompletedElderly Patients Undergoing Trans Pars Plana Vitrectomy With General AnesthesiaKorea, Republic of
-
PromiSight, LLCNot yet recruitingPars Plana Vitrectomy
-
Ospedale Policlinico San MartinoRecruitingRetinal Detachment | PArs Plana Vitrectomy | Silicone Oil Droplets on Intraocular LensItaly
-
Johns Hopkins UniversitySARcode BioscienceTerminatedPars Plana Vitrectomy | Diabetic Macular Edema (DME)United States
-
Tianjin Medical University Eye HospitalRecruitingDiabetic Macular Edema | Pars Plana Vitrectomy | ConberceptChina
-
Tanta UniversityCompletedMyopic Traction Maculopathy | Pars Plana Vitrectomy | Internal Limiting Membrane Peeling
-
Tianjin Medical University Eye HospitalAbbvie Pharmaceutical Trading (Shanghai) Co., Ltd.RecruitingDiabetic Macular Edema | Pars Plana Vitrectomy | Dexamethasone Intravitreal Implant | Intraoperative Optical Coherence TomographyChina
-
Tianjin Medical University Eye HospitalHebei Provincial Eye Hospital; Cangzhou Eye HospitalRecruitingDiabetic Retinopathy | Pars Plana Vitrectomy | Ranibizumab | Postoperative Recurrent Vitreous HemorrhageChina
-
Iran University of Medical SciencesCompletedDiabetic Retinopathy | Pars Plana Vitrectomy | Intravitreal Bevacizumab Injection | Tractional Retinal DetachmentIran, Islamic Republic of
-
Tianjin Medical University Eye HospitalRecruitingProliferative Diabetic Retinopathy | Pars Plana Vitrectomy | Risk Prediction ModelChina
Clinical Trials on Suprachoroidal hemorrhage associated with pars plana vitrectomy
-
Klinikum Chemnitz gGmbHCompletedAge Related Macular Degeneration | Epiretinal Membrane | Macular HolesGermany
-
Centre Hospitalier Universitaire DijonCompletedPostoperative Complications | Intraocular Pressure,France
-
Benha UniversityRecruiting
-
PharmaBio CorporationRecruitingMyopic Chorioretinal AtrophyJapan
-
Ospedale Policlinico San MartinoRecruitingRetinal Detachment | PArs Plana Vitrectomy | Silicone Oil Droplets on Intraocular LensItaly
-
Ospedale Policlinico San MartinoRecruiting
-
Omer Othman AbdullahTerminated
-
Minia UniversityCompleted
-
AllerganCompletedVitrectomyUnited States
-
Benha UniversityRecruitingRetinal Detachment | Proliferative VitreoretinopathyEgypt